Quarterly ResultMay 14, 2026, 04:08 PM
Daré Bioscience Q1 Net Loss $(3.0)M; First Product Revenue Expected June 2026
AI Summary
Daré Bioscience reported a Q1 2026 net loss of $(3.0) million, an improvement from $(4.4) million in Q1 2025, with revenue increasing to $0.2 million. The company anticipates its first direct product revenue in June 2026 from the commercial launch of Flora Sync LF5™ and expects DARE to PLAY™ dispensing to commence in Summer 2026. Additionally, Ovaprene® received a second positive DSMB review for its Phase 3 trial, and DARE-HPV is advancing to Phase 2.
Key Highlights
- Net loss improved to $(3.0) million in Q1 2026 from $(4.4) million in Q1 2025.
- Revenue increased to $0.2 million in Q1 2026 from $25,427 in Q1 2025.
- R&D expenses decreased to $0.7 million in Q1 2026, supported by $3.5 million in contra-R&D grants.
- Cash and cash equivalents were $18.5 million as of March 31, 2026.
- Flora Sync LF5™ commercial launch and first direct product revenue expected in June 2026.
- DARE to PLAY™ dispensing anticipated to commence in Summer 2026 (Q3 2026).
- Ovaprene® Phase 3 trial received a second positive DSMB review; enrollment completion expected 2026.
- DARE-HPV advancing into Phase 2 clinical study in May 2026 with ARPA-H funding.